검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | combination (Vemurafenib plus Cobimetinib, Vemurafenib plus Cobimetinib (combination)) Ulrik Lassen·Cancer ORR 94% |
|---|---|
Overview Program | Vemurafenib plus Cobimetinib (combination) |
Overview Company | Ulrik Lassen |
Overview Modality | ADC |
Overview Target | Cancer |
Overview Indication | Cancer; Tumors |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | of ProAgio, which includes reducing hypoxia and modulating TME |
MoA Biomarker | biomarkers and sex hormone receptor profiles in assessing post-surgical prognosis among HCC patients |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Clinical efficacy and safety of tenecteplase combined with argatroban for acute ischemic stroke: A single-center retrospective cohort study.. Acute ischemic stroke remains a major cause of death and disability, and intravenous thrombolysis is central to early reperfusion; however, post-lysis thrombin activity may contribute to rethrombosis and incomplete reperfusion. We conducted a single-center r… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 94% |
Clinical ORR | 94% |
Clinical PFS | 0.87 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03224767 |
Clinical Data Tier / Score | A · 71 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | combination (Vemurafenib plus Cobimetinib, Vemurafenib plus Cobimetinib (combination)) Ulrik Lassen·Cancer ORR 94% |
|---|---|
Overview Program | Vemurafenib plus Cobimetinib (combination) |
Overview Company | Ulrik Lassen |
Overview Modality | ADC |
Overview Target | Cancer |
Overview Indication | Cancer; Tumors |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | of ProAgio, which includes reducing hypoxia and modulating TME |
MoA Biomarker | biomarkers and sex hormone receptor profiles in assessing post-surgical prognosis among HCC patients |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Clinical efficacy and safety of tenecteplase combined with argatroban for acute ischemic stroke: A single-center retrospective cohort study.. Acute ischemic stroke remains a major cause of death and disability, and intravenous thrombolysis is central to early reperfusion; however, post-lysis thrombin activity may contribute to rethrombosis and incomplete reperfusion. We conducted a single-center r… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 94% |
Clinical ORR | 94% |
Clinical PFS | 0.87 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03224767 |
Clinical Data Tier / Score | A · 71 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교